Miyuki Azuma mostly deals with T cell, Immunology, Cell biology, CD8 and Immune system. Her T cell research incorporates themes from Cytotoxic T cell, Molecular biology and Phosphorylation. Her research investigates the connection between Immunology and topics such as Blockade that intersect with issues in MHC class I.
Her Cell biology study integrates concerns from other disciplines, such as Peripheral tolerance, Cell, Natural killer cell and Cytokine. Her CD8 research is multidisciplinary, incorporating elements of Cancer research and Transplantation. The Immune system study combines topics in areas such as Monoclonal antibody, PTEN and Pathology.
The scientist’s investigation covers issues in Immunology, T cell, Immune system, Cell biology and Cancer research. The various areas that Miyuki Azuma examines in her Immunology study include Cytotoxic T cell and Blockade. Her studies deal with areas such as Molecular biology, CD8 and Cytokine as well as T cell.
Her studies in Immune system integrate themes in fields like Inflammation, Internal medicine, Pathogenesis and Pathology. Her research integrates issues of Peripheral tolerance, Cell, Receptor and T-cell receptor in her study of Cell biology. Miyuki Azuma has researched Cancer research in several fields, including Leukemia and Immunotherapy.
Miyuki Azuma spends much of her time researching Immunology, Immune system, T cell, Cell biology and CD8. Her study brings together the fields of Downregulation and upregulation and Immunology. Her Immune system research incorporates elements of Carcinogenesis and Agonist.
Her study in T cell is interdisciplinary in nature, drawing from both Immune checkpoint, Receptor, Blockade, Cytokine and Cytotoxic T cell. Her Cell biology research is multidisciplinary, relying on both Suppressor, Cell and Interleukin 10. Her work carried out in the field of CD8 brings together such families of science as Cancer research, Antibody-dependent cell-mediated cytotoxicity and PD-L1.
Immunology, T cell, Immune system, Blockade and Immune checkpoint are her primary areas of study. Her Immunology research includes elements of Downregulation and upregulation and CD11c. She focuses mostly in the field of T cell, narrowing it down to topics relating to Cytokine and, in certain cases, Antibody, Immunohistochemistry and Cancer immunotherapy.
Her Immune system study incorporates themes from Cell signaling, Type 1 diabetes, PTEN and Cell biology. Her research in Blockade intersects with topics in PD-L1 and Haematopoiesis. Her Immune checkpoint research is multidisciplinary, incorporating perspectives in Tumor microenvironment, CTLA-4, Cancer research and CD8.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Tomohide Yamazaki;Hisaya Akiba;Hideyuki Iwai;Hironori Matsuda.
Journal of Immunology (2002)
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Takeo Nomi;Masayuki Sho;Takahiro Akahori;Kaoru Hamada.
Clinical Cancer Research (2007)
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Yuichiro Ohigashi;Masayuki Sho;Yukishige Yamada;Yoshikazu Tsurui.
Clinical Cancer Research (2005)
B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression
Jun Konishi;Koichi Yamazaki;Miyuki Azuma;Ichiro Kinoshita.
Clinical Cancer Research (2004)
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Mohammed Javeed I. Ansari;Alan D. Salama;Alan D. Salama;Tanuja Chitnis;Tanuja Chitnis;R. Neal Smith.
Journal of Experimental Medicine (2003)
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
Madhav D. Sharma;Babak Baban;Phillip Chandler;De Yan Hou.
Journal of Clinical Investigation (2007)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.
Tadashi Yokosuka;Masako Takamatsu;Wakana Kobayashi-Imanishi;Akiko Hashimoto-Tane.
Journal of Experimental Medicine (2012)
CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.
L L Lanier;S O'Fallon;C Somoza;J H Phillips.
Journal of Immunology (1995)
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis
Alan D. Salama;Tanuja Chitnis;Tanuja Chitnis;Jaime Imitola;Jaime Imitola;Mohammed Javeed I. Ansari.
Journal of Experimental Medicine (2003)
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.
Juro Nakanishi;Yoshihiro Wada;Koichiro Matsumoto;Miyuki Azuma.
Cancer Immunology, Immunotherapy (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: